Dehaier Medical Renews High and New Technology Enterprises Status


BEIJING, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has received approval from PRC authorities for the renewal of its "High and New Technology Enterprises" ("HNTE") status through 2015.

Mr. Ping Chen, Chief Executive Officer of Dehaier Medical, commented, "We are pleased that Dehaier has successfully renewed its HNTE status, which permits us to pay a preferential corporate income tax rate of 15%, rather than the ordinary 25% rate, in 2012, 2013 and 2014. The renewal recognizes our R&D efforts and reflects years of operation as a high-tech company. The HNTE designation makes our company eligible to apply for other benefits as well, including government support. For example, Dehaier recently received government subsidies worth RMB118,100 for short-term bank loan interest, as a result of favorable treatment granted to High Technology Enterprises."  

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier's technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the status as a high-tech enterprise. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.



            

Contact Data